Research ExplorerPublicationsDefining a Standard Set of Patient-centered Outcomes for Men...

Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer

Standard

Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. / Martin, Neil E; Massey, Laura; Stowell, Caleb; Bangma, Chris; Briganti, Alberto; Bill-Axelson, Anna; Blute, Michael; Catto, James; Chen, Ronald C; D'Amico, Anthony V; Feick, Günter; Fitzpatrick, John M; Frank, Steven J; Froehner, Michael; Frydenberg, Mark; Glaser, Adam; Graefen, Markus; Hamstra, Daniel; Kibel, Adam; Mendenhall, Nancy; Moretti, Kim; Ramon, Jacob; Roos, Ian; Sandler, Howard; Sullivan, Francis J; Swanson, David; Tewari, Ashutosh; Vickers, Andrew; Wiegel, Thomas; Huland, Hartwig.

In: EUR UROL, Vol. 67, No. 3, 01.03.2015, p. 460-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Martin, NE, Massey, L, Stowell, C, Bangma, C, Briganti, A, Bill-Axelson, A, Blute, M, Catto, J, Chen, RC, D'Amico, AV, Feick, G, Fitzpatrick, JM, Frank, SJ, Froehner, M, Frydenberg, M, Glaser, A, Graefen, M, Hamstra, D, Kibel, A, Mendenhall, N, Moretti, K, Ramon, J, Roos, I, Sandler, H, Sullivan, FJ, Swanson, D, Tewari, A, Vickers, A, Wiegel, T & Huland, H 2015, 'Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer', EUR UROL, vol. 67, no. 3, pp. 460-7. https://doi.org/10.1016/j.eururo.2014.08.075

APA

Martin, N. E., Massey, L., Stowell, C., Bangma, C., Briganti, A., Bill-Axelson, A., Blute, M., Catto, J., Chen, R. C., D'Amico, A. V., Feick, G., Fitzpatrick, J. M., Frank, S. J., Froehner, M., Frydenberg, M., Glaser, A., Graefen, M., Hamstra, D., Kibel, A., ... Huland, H. (2015). Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. EUR UROL, 67(3), 460-7. https://doi.org/10.1016/j.eururo.2014.08.075

Vancouver

Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. EUR UROL. 2015 Mar 1;67(3):460-7. https://doi.org/10.1016/j.eururo.2014.08.075

Bibtex

@article{876834acf21d433081ebbb2b69e7c54f,
title = "Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer",
abstract = "BACKGROUND: Value-based health care has been proposed as a unifying force to drive improved outcomes and cost containment.OBJECTIVE: To develop a standard set of multidimensional patient-centered health outcomes for tracking, comparing, and improving localized prostate cancer (PCa) treatment value.DESIGN, SETTING, AND PARTICIPANTS: We convened an international working group of patients, registry experts, urologists, and radiation oncologists to review existing data and practices.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The group defined a recommended standard set representing who should be tracked, what should be measured and at what time points, and what data are necessary to make meaningful comparisons. Using a modified Delphi method over a series of teleconferences, the group reached consensus for the Standard Set.RESULTS AND LIMITATIONS: We recommend that the Standard Set apply to men with newly diagnosed localized PCa treated with active surveillance, surgery, radiation, or other methods. The Standard Set includes acute toxicities occurring within 6 mo of treatment as well as patient-reported outcomes tracked regularly out to 10 yr. Patient-reported domains of urinary incontinence and irritation, bowel symptoms, sexual symptoms, and hormonal symptoms are included, and the recommended measurement tool is the Expanded Prostate Cancer Index Composite Short Form. Disease control outcomes include overall, cause-specific, metastasis-free, and biochemical relapse-free survival. Baseline clinical, pathologic, and comorbidity information is included to improve the interpretability of comparisons.CONCLUSIONS: We have defined a simple, easily implemented set of outcomes that we believe should be measured in all men with localized PCa as a crucial first step in improving the value of care.PATIENT SUMMARY: Measuring, reporting, and comparing identical outcomes across treatments and treatment centers will provide patients and providers with information to make informed treatment decisions. We defined a set of outcomes that we recommend being tracked for every man being treated for localized prostate cancer.",
author = "Martin, {Neil E} and Laura Massey and Caleb Stowell and Chris Bangma and Alberto Briganti and Anna Bill-Axelson and Michael Blute and James Catto and Chen, {Ronald C} and D'Amico, {Anthony V} and G{\"u}nter Feick and Fitzpatrick, {John M} and Frank, {Steven J} and Michael Froehner and Mark Frydenberg and Adam Glaser and Markus Graefen and Daniel Hamstra and Adam Kibel and Nancy Mendenhall and Kim Moretti and Jacob Ramon and Ian Roos and Howard Sandler and Sullivan, {Francis J} and David Swanson and Ashutosh Tewari and Andrew Vickers and Thomas Wiegel and Hartwig Huland",
note = "Copyright {\textcopyright} 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2015",
month = mar,
day = "1",
doi = "10.1016/j.eururo.2014.08.075",
language = "English",
volume = "67",
pages = "460--7",
journal = "EUR UROL",
issn = "0302-2838",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer

AU - Martin, Neil E

AU - Massey, Laura

AU - Stowell, Caleb

AU - Bangma, Chris

AU - Briganti, Alberto

AU - Bill-Axelson, Anna

AU - Blute, Michael

AU - Catto, James

AU - Chen, Ronald C

AU - D'Amico, Anthony V

AU - Feick, Günter

AU - Fitzpatrick, John M

AU - Frank, Steven J

AU - Froehner, Michael

AU - Frydenberg, Mark

AU - Glaser, Adam

AU - Graefen, Markus

AU - Hamstra, Daniel

AU - Kibel, Adam

AU - Mendenhall, Nancy

AU - Moretti, Kim

AU - Ramon, Jacob

AU - Roos, Ian

AU - Sandler, Howard

AU - Sullivan, Francis J

AU - Swanson, David

AU - Tewari, Ashutosh

AU - Vickers, Andrew

AU - Wiegel, Thomas

AU - Huland, Hartwig

N1 - Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - BACKGROUND: Value-based health care has been proposed as a unifying force to drive improved outcomes and cost containment.OBJECTIVE: To develop a standard set of multidimensional patient-centered health outcomes for tracking, comparing, and improving localized prostate cancer (PCa) treatment value.DESIGN, SETTING, AND PARTICIPANTS: We convened an international working group of patients, registry experts, urologists, and radiation oncologists to review existing data and practices.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The group defined a recommended standard set representing who should be tracked, what should be measured and at what time points, and what data are necessary to make meaningful comparisons. Using a modified Delphi method over a series of teleconferences, the group reached consensus for the Standard Set.RESULTS AND LIMITATIONS: We recommend that the Standard Set apply to men with newly diagnosed localized PCa treated with active surveillance, surgery, radiation, or other methods. The Standard Set includes acute toxicities occurring within 6 mo of treatment as well as patient-reported outcomes tracked regularly out to 10 yr. Patient-reported domains of urinary incontinence and irritation, bowel symptoms, sexual symptoms, and hormonal symptoms are included, and the recommended measurement tool is the Expanded Prostate Cancer Index Composite Short Form. Disease control outcomes include overall, cause-specific, metastasis-free, and biochemical relapse-free survival. Baseline clinical, pathologic, and comorbidity information is included to improve the interpretability of comparisons.CONCLUSIONS: We have defined a simple, easily implemented set of outcomes that we believe should be measured in all men with localized PCa as a crucial first step in improving the value of care.PATIENT SUMMARY: Measuring, reporting, and comparing identical outcomes across treatments and treatment centers will provide patients and providers with information to make informed treatment decisions. We defined a set of outcomes that we recommend being tracked for every man being treated for localized prostate cancer.

AB - BACKGROUND: Value-based health care has been proposed as a unifying force to drive improved outcomes and cost containment.OBJECTIVE: To develop a standard set of multidimensional patient-centered health outcomes for tracking, comparing, and improving localized prostate cancer (PCa) treatment value.DESIGN, SETTING, AND PARTICIPANTS: We convened an international working group of patients, registry experts, urologists, and radiation oncologists to review existing data and practices.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The group defined a recommended standard set representing who should be tracked, what should be measured and at what time points, and what data are necessary to make meaningful comparisons. Using a modified Delphi method over a series of teleconferences, the group reached consensus for the Standard Set.RESULTS AND LIMITATIONS: We recommend that the Standard Set apply to men with newly diagnosed localized PCa treated with active surveillance, surgery, radiation, or other methods. The Standard Set includes acute toxicities occurring within 6 mo of treatment as well as patient-reported outcomes tracked regularly out to 10 yr. Patient-reported domains of urinary incontinence and irritation, bowel symptoms, sexual symptoms, and hormonal symptoms are included, and the recommended measurement tool is the Expanded Prostate Cancer Index Composite Short Form. Disease control outcomes include overall, cause-specific, metastasis-free, and biochemical relapse-free survival. Baseline clinical, pathologic, and comorbidity information is included to improve the interpretability of comparisons.CONCLUSIONS: We have defined a simple, easily implemented set of outcomes that we believe should be measured in all men with localized PCa as a crucial first step in improving the value of care.PATIENT SUMMARY: Measuring, reporting, and comparing identical outcomes across treatments and treatment centers will provide patients and providers with information to make informed treatment decisions. We defined a set of outcomes that we recommend being tracked for every man being treated for localized prostate cancer.

U2 - 10.1016/j.eururo.2014.08.075

DO - 10.1016/j.eururo.2014.08.075

M3 - SCORING: Journal article

C2 - 25234359

VL - 67

SP - 460

EP - 467

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 3

ER -